Maykin Ho - 13 Feb 2025 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role
Director
Signature
/s/ Michael Milligan, as Attorney-in-Fact for Maykin Ho
Issuer symbol
NMRA
Transactions as of
13 Feb 2025
Net transactions value
$0
Form type
4
Filing time
18 Feb 2025, 16:30:08 UTC
Previous filing
24 Jun 2024
Next filing
22 May 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -95,586 -100% 0 13 Feb 2025 Common Stock 95,586 $2.51 Direct F1, F2
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -27,802 -100% 0 13 Feb 2025 Common Stock 27,802 $17.00 Direct F1, F2
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -28,571 -100% 0 13 Feb 2025 Common Stock 28,571 $9.95 Direct F2, F3
transaction NMRA Stock Option (Right to Buy) Award +95,586 95,586 13 Feb 2025 Common Stock 95,586 $1.69 Direct F1, F2, F4
transaction NMRA Stock Option (Right to Buy) Award +27,802 27,802 13 Feb 2025 Common Stock 27,802 $1.69 Direct F1, F2, F4
transaction NMRA Stock Option (Right to Buy) Award +28,571 28,571 13 Feb 2025 Common Stock 28,571 $1.69 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option is fully vested and exercisable.
F2 On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged.
F3 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024.
F4 Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.